What Are Those RNA Modifications Doing for Gene Regulation?

·28 min·1 clip

Pluripotent stem cells cannot differentiate without M6A, and cancer cells use M6A to evade apoptosis.

1. cc: Life Science Podcast focuses on RNA modifications and gene regulation with Goodwin Stengel of Alita Biosciences. 2. Goodwin Stengel is the CEO and co-founder of Alita Biosciences, and Nikita Warner connected the interview. 3. The episode asks how RNA modifications regulate gene expression and why Alita is building tools around that question. 4. Stengel says RNA modifications affect alternative splicing, translation initiation, translation efficiency, protein production yields, cell trafficking, and messenger RNA half-life. 5. He describes RNA modifications as a kind of fine-tuning with quick on-off switches rather than a simple switch. 6. The most studied example is m6A, and he says all modifications act through writer, eraser, and reader proteins. 7. He names the YTH reader family as at least five proteins that can stabilize RNA, destabilize RNA, alter splicing, or change translation initiation complex formation. 8. He says pluripotent stem cells cannot differentiate without M6A, and that METTL3 knockout blocks embryonic stem-cell differentiation. 9. He also says METTL3 is upregulated in cancers such as leukemia, neuroblastoma, and glioblastoma, where it stabilizes pro-survival mRNAs. 10. He notes studies suggesting METTL3 inhibition during chemotherapy can make resistant cells less able to evade treatment. 11. Stengel says about 170 RNA modifications have been identified across mammals, bacteria, archaea, and viruses. 12. He says humans have about 25 unique modified bases and about 50 total modifications when sugar modifications are counted. 13. He contrasts tRNA, where about every fifth base is modified and the pattern is relatively static, with mRNA, where modifications are dynamic and environmentally responsive. 14. He names m6A, inosine, and pseudouridine as the most prominent mRNA modifications by mass. 15. He says low abundance is a major technical problem, because m6A can occur at up to 1% of adenosines and many other marks are at 0.1% or 0.01%. 16. He also says there is no reference genome for RNA modifications, so validation depends on spike-ins, knockout cell lines, in vitro transcripts, and public-data comparisons that often show only about 30% concordance. 17. He describes the older mass-spectrometry approach as broad but not sequence-resolved, and says antibody pulldown methods around 2014 began the sequence-resolved era. 18. He explains that Alita’s Epiplex platform uses proximity barcoding, an NGS readout, and protein binders selected for higher specificity after antibody experiments fell short. 19. This interview is technical and explanatory, with Stengel answering follow-up questions about biology, assay design, diagnostics, and company strategy. 20. Listeners interested in RNA biology, sequencing technology, or epitranscriptomics will get the most from it, while casual listeners looking for light conversation may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from cc: Life Science Podcast